Navigation Links
BGI Tech and BAB jointly develop transgenic mice platform for biomedical research

August 7, 2012, Shenzhen, China BGI Tech Solutions Co., LTD, also referred to as "BGI Tech" and BGI Ark Biotechnology Co., LTD. (BAB), a biotechnology company dedicated to large scale production of transgenic and cloned animals, today announced that they have jointly developed an advanced transgenic mice platform for boosting human diseases and medical research, with the advantages of improved efficiency, high positive rate, available sex determination, fast turnaround time, and low cost.

In contrast to traditional transgenic techniques, the platform could provide more comprehensive technical services to efficiently generate transgenic mice for researchers worldwide. It covers a wide range of techniques and services, including DNA microinjection, blastocyst injection and tetraploid complementation assay, gene knockin, gene knockout and conditional gene knockout, targeting vector construction, embryo cryopreservation, in vitro fertilization (IVF) and embryo transfer, among others.

Transgenic mice serve as important models for embryonic development and disease pathogenesis research, and their use has dramatically increased for the past two decades. The mice and cell lines derived from them have also accelerated basic research by allowing scientists to relate functions to genes, dissect genetic pathways, and manipulate the cellular or biochemical properties of proteins.

"Based on the handmade cloning and sperm-mediated technologies, we could provide more efficient and economic access to transgenic mice and related research." said, Dr. Yutao Du, Director of BAB, and Vice President of BGI, "We have established a SPF-level facility covering 160 square meters, which could house more than 2,000 mice. The platform also has equipped with the full set of professional experimental equipment and a number of technical experts." she added.

With the high-throughput sequencing platform and profound experience in genomics, BGI Tech in addition provides solutions for gene detection, transgenic mice construction and gene function evaluation. Na Liu, Director of Product Management at BGI Tech, said, "There are significant research and commercial needs for a large scale transgenic mouse platform. We not only can provide the excellent transgenic tech support, but also work with researchers to design professional and personalized solutions. The combination of transgenic technology and high throughput sequencing technology will become an inevitable trend for genetic engineering and make great improvement in biomedical research and applications."

Contact: Jia Liu
BGI Shenzhen

Related biology news :

1. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
2. Diabetes Research Institute develops oxygen-generating biomaterial
3. Artificial womb unlocks secrets of early embryo development
4. REST is crucial for the timing of brain development
5. Embryonic development protein active in cancer growth
6. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
7. Mini-CT scanner developed as a teaching tool
8. Genetic research develops tools for studying diseases, improving regenerative treatment
9. Oceanographers develop method for measuring the pace of life in deep sediments
10. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
11. Stomata development in plants unraveled -- a valuable discovery for environmental research
Post Your Comments:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology: